Brentuximab Vedotin clinical trials
Also written Adcetris, SGN-35 and cAC10-vcMMAE.
How each study uses Brentuximab Vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Brentuximab Vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Aug 2011 · ADCETRIS · BLA 125388 (FDA, Drugs@FDA)
- European Union
- 25 Oct 2012 · Adcetris · EMEA/H/C/002455 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
153 studies that test it; most in 2013 (24); 1 more planned to start later
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 7 |
| 2012 | 10 |
| 2013 | 24 |
| 2014 | 12 |
| 2015 | 14 |
| 2016 | 12 |
| 2017 | 10 |
| 2018 | 13 |
| 2019 | 8 |
| 2020 | 6 |
| 2021 | 4 |
| 2022 | 10 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 37 · Other 117
Seagen Inc. (21) · City of Hope Medical Center (9) · National Cancer Institute (NCI) (8) · Takeda (7) · M.D. Anderson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (5) · Massachusetts General Hospital (5) · Fondazione Italiana Linfomi - ETS (5)
Often tested with
Tested in the same studies.
Nivolumab (16) · Dacarbazine (16) · Doxorubicin (15) · Vinblastine (11) · Pembrolizumab (11) · Etoposide (9) · Cyclophosphamide (8) · Rituximab (6)
Related medicines
As reviewed, each with the page that says it.
- One of Antibody-drug conjugates (ADCs) source
- One of Immunotoxins source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 11
Studies that test Brentuximab Vedotin.
- Dec 2026Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaPhase 2 · Canadian Cancer Trials Group
- Jan 2027Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Phase 2 · St. Jude Children's Research Hospital
- Jan 2027Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesPhase 2 · M.D. Anderson Cancer Center
- Apr 2027A Study of BV-AVD in People With Bulky Hodgkin LymphomaPhase 2 · Memorial Sloan Kettering Cancer Center
- May 2027Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by SurgeryPhase 2 · M.D. Anderson Cancer Center
- Jul 2027Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsPhase 2 · Memorial Sloan Kettering Cancer Center
- Aug 2027PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyPhase 2 · M.D. Anderson Cancer Center
- Oct 2027Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaPhase 2 · City of Hope Medical Center
- Oct 2027Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and AbovePhase 2 · University of Virginia
- Oct 2027PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses Brentuximab Vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 154
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Brentuximab Vedotin
- Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentRecruitingPhase 2City of Hope Medical CenterNCT07275216Written as Brentuximab Vedotin
- Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRecruitingPhase 2City of Hope Medical CenterNCT04561206Written as Brentuximab Vedotin
- Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecruitingPhase 2Emory UniversityNCT05039073Written as Brentuximab Vedotin
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaRecruitingEarly Phase 1New York Medical CollegeNCT03719105Written as Brentuximab Vedotin
- Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05357794Written as Brentuximab vedotin
- Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaNot yet recruitingPhase 2/3National Cancer Institute (NCI)NCT07572123Written as Brentuximab Vedotin
- Brentuximab Vedotin in Early Stage Hodgkin LymphomaRecruitingPhase 3University College, LondonNCT04685616Written as Brentuximab vedotin
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingPhase 2Yale UniversityNCT05313243Written as Brentuximab vedotin
- Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLRecruitingPhase 2New York Medical CollegeNCT07013565Written as Brentuximab vedotin (Adcetris)
- A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06377566Written as Brentuximab vedotin
- Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT AssessmentRecruitingPhase 2/3Children's Cancer Group, ChinaNCT06563245Written as Brentuximab Vedotin for Injection
- A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaRecruitingPhase 4TakedaNCT06831370Written as Brentuximab Vedotin
- PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingPhase 2M.D. Anderson Cancer CenterNCT04745949Written as Brentuximab Vedotin
- Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2Canadian Cancer Trials GroupNCT05180097Written as Brentuximab vedotin
- BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell LymphomasEnrolling by invitationPhase 3N.N. Petrov National Medical Research Center of OncologyNCT07258680Written as Brentuximab Vedotin (Bv)
- BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruitingPhase 2University of MiamiNCT07002216Written as Brentuximab Vedotin
- Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant MaintenanceNot yet recruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT07178457Written as Brentuximab Vedotin (Bv)
- Treatment Strategy for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2/3Hospital Regional de Alta Especialidad del BajioNCT05595447Written as Brentuximab Vedotin 50 MG [Adcetris]
- BREntuximab Vedotin in SEcond LIne Therapy BEfore TransplantRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT04378647Written as Induction with Brentuximab vedotin (BV)
See all 154 studies that test Brentuximab Vedotin →
Given beside what is tested · 15 — Brentuximab Vedotin is usual care or a partner of the new treatment
- Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)Not yet recruitingPhase 2Peking University First HospitalNCT07717580Written as Brentuximab Vedotin (Bv)
- BV in the Treatment of Relapsed/refractory Hodgkin LymphomaNot yet recruitingPhase 4Xiuhua SunNCT06761911Written as Brentuximab Vedotin (Bv)
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01896999Written as Brentuximab Vedotin
- Clinical Trial of Brentuximab Vedotin in Classical Hodgkin LymphomaTerminatedPhase 2Seagen Inc.NCT03646123Written as brentuximab vedotin
- A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentCompletedPhase 2Bristol-Myers SquibbNCT02927769Written as brentuximab vedotin
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedPhase 1Seagen Inc.NCT04254107Written as brentuximab vedotin
- A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaWithdrawnPhase 3National Cancer Institute (NCI)NCT05711628Written as Brentuximab Vedotin
- Brentuximab for Newly Diagnosed Hodgkin DiseaseCompletedPhase 2Mitchell CairoNCT02398240Written as Brentuximab Vedotin
- Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma PatientsStatus unknownPhase 1/2New York Medical CollegeNCT02098512Written as Brentuximab Vedotin
- A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)WithdrawnPhase 2Yale UniversityNCT04138875Written as Brentuximab Vedotin
- Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell LymphomaStatus unknownPhase 2Shanghai Zhongshan HospitalNCT05316246Written as Brentuximab Vedotin in Combination with Tislelizumab
- Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma PatientsCompletedPhase 1TG Therapeutics, Inc.NCT02164006Written as TGR-1202 + brentuximab vedotin
- Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin LymphomaCompletedPhase 2University of CologneNCT01569204Written as Brentuximab Vedotin
- Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid MalignanciesWithdrawnPhase 1Eric Bernicker, MDNCT02780011Written as Brentuximab Vedotin
- Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnPhase 1M.D. Anderson Cancer CenterNCT03205891Written as Brentuximab Vedotin
As the comparator · 1 — what is tested is compared with Brentuximab Vedotin
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted2
Codes
What other systems call Brentuximab Vedotin · ClinicalTrials.gg INT006839
- MeSH (NLM) D000079963Brentuximab VedotinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7XL5ISS668BRENTUXIMAB VEDOTINConfirmed FDA, NLM, Wikidata
- RxNorm 1147320Confirmed FDA, Wikidata
- Wikidata Q422324brentuximab vedotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66944Brentuximab VedotinOne source FDA
- DrugBank DB08870One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000079963 | Brentuximab Vedotin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7XL5ISS668 | BRENTUXIMAB VEDOTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1147320 | — | Confirmed FDA, Wikidata |
| Wikidata | Q422324 | brentuximab vedotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66944 | Brentuximab Vedotin | One source FDA |
| DrugBank | DB08870 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.